OXELTIS
OXELTIS is an independent medicinal chemistry CRO founded in 2010 in Montpellier, France, providing specialized synthesis and drug discovery services in nucleos(t)ides, heterocycles and macrocycles to pharmaceutical, biotech, diagnostic and academic clients worldwide.
- Company typePrivate
- Founded2010
- HeadquartersMontpellier, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What OXELTIS does
OXELTIS is an independent, privately held medicinal chemistry Contract Research Organization (CRO) founded in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company delivers specialized drug discovery services to pharmaceutical, biotechnology, diagnostic and academic clients, with deep technical focus on nucleos(t)ide chemistry, heterocyclic and macrocyclic compounds, mono- and oligo/polysaccharides, and phosphorus and fluorine chemistry. Its scientific team is PhD-heavy (approximately 50%), and the firm has synthesized more than 1,500 complex nucleos(t)ides over fifteen years, including prodrugs, phosphoramidites and triphosphates, with several drug candidates delivered to clients now in clinical development.
The service portfolio is organized around two core offerings — Medicinal Chemistry Services (hit-to-lead optimization, lead generation and optimization, SAR analysis, FTE-based project support) and Fine Organic Chemistry / Custom Synthesis (mg to 50-100g scale, with external partner collaboration up to kg lab scale) — supported by three proprietary technology platforms: Flow Chemistry (continuous processing for reactive intermediates and scale-up), SFC Purification Platform (chiral/achiral separations, mg to 25g/day), and Mechanochemistry (sustainable solid-state synthesis). Revenue is generated through fee-for-service quotes (typically delivered within 48 hours) and FTE-based multi-year contracts, complemented by scale-up services and risk/IP-sharing partnerships for academic and grant-funded programs. The go-to-market is sales-led and event-driven, with a direct CEO-led EU motion supplemented by TechGateUS (North America) and Biocomm² (Japan) channel partners, and heavy participation in industry conferences such as Gordon Research Conferences, BIO, EFMC, ACSMEDI and RICT. OXELTIS reports 35+ biotech and pharma clients including 5 of top 10 global pharma, 70-80% export-derived turnover across Europe, North America and Japan, ISO 9001:2015 certification obtained in December 2024, and 100% year-over-year turnover growth in 2021 versus 2020.
OXELTIS firmographics
Firmographics- Name
- OXELTIS
- Legal name
- Oxeltis
- Website
- https://oxeltis.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- OXELTIS is an independent medicinal chemistry CRO founded in 2010 in Montpellier, France, providing specialized synthesis and drug discovery services in nucleos(t)ides, heterocycles and macrocycles to pharmaceutical, biotech, diagnostic and academic clients worldwide.
- Ownership category
- akta.pro rank
OXELTIS industry classification
Industry- Product category
- Contract Research Organization (Drug Discovery Chemistry Services)
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
Keywords
Where OXELTIS is headquartered
LocationHeadquarters
- HQ city
- Montpellier
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
OXELTIS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Fee-for-Service / FFS: Custom synthesis and medicinal chemistry services billed per project or per compound delivered. Quotations provided within 48 hours for initial study.
- FTE-based Contracts: Full-Time Equivalent staffing model where medicinal chemists work dedicated hours on client projects, typically for longer-term programs.
- Scale-up and Production Services: Route scouting and early scale-up services from 50-100g, with external partners for 20g to Kg lab scale-up optimization and synthesis (GMP or non-GMP).
- Partnership with Risk/IP Sharing: Collaborative arrangements involving risk or IP sharing for academic programs, research collaborations, and grant applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Fee-for-service model with tailored solutions |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
OXELTIS product offering
Product offeringCore offering
OXELTIS is an independent medicinal chemistry oriented service company (CRO) that provides competencies and resources for projects involving medicinal and fine organic chemistry in pharmaceutical, diagnostic and academic research. It delivers custom synthesis of complex organic molecules including nucleos(t)ides, heterocyclic and macrocyclic compounds, phosphoramidites, and modified sugars, supporting hit-to-lead and lead optimization in drug discovery, with route scouting and scale-up from mg to ~100 g.
Product overview
OXELTIS is a medicinal chemistry and custom synthesis CRO (Contract Research Organization) offering a portfolio of services organized around two core offerings: Medicinal Chemistry Services and Fine Organic Chemistry/Custom Synthesis. These are supported by three technology platforms — Flow Chemistry, SFC Purification Platform, and Mechanochemistry — that enhance synthesis capabilities. The company provides FTE-based and fee-for-service models for drug discovery programs in antivirals, antibacterials, and oncology, from early hit-to-lead through scale-up to 100g.
Differentiator
Problem solved
Functional benefit
Products and services
- Medicinal Chemistry Services Drug discovery medicinal chemistry services including bibliographic and IP research, hit-to-lead optimization, lead generation and optimization, drug candidate selection, small focused library sets, SAR interpretation, and FTE-based project support for pharmaceutical and biotech clients.
- Fine Organic Chemistry / Custom Synthesis Custom synthesis of complex organic molecules including base- and sugar-modified nucleoside analogues, nucleoside mono-/di-/triphosphates, phosphoramidites, di-nucleotides, mono- and oligosaccharides, heterocycles, macrocycles, peptides, TPD/PROTACs and ADC linkers, from mg to 50–100 g with partner-supported scale-up to kg.
Quantifiable outcome
- More than 1,500 complex nucleos(t)ides synthesized with extensive modifications
- +3 more outcomes
Companies that use OXELTIS
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles4 records
OXELTIS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
OXELTIS partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor, flagship and core.
- IASO Discovery, Diverchim & ARNAminorCollaborative participation in 1st French Therapeutic Oligonucleotides Day event to accelerate development of therapeutic oligonucleotides in France. Christophe Parsy spoke during round table on technical solutions for oligonucleotide development.
- Lead PharmaflagshipThree-year EPIGENEXT joint project awarded €800K Eureka Eurostars grant for developing first-in-class therapy for diffuse large B-cell lymphoma (DLBCL). Oxeltis contributes medicinal chemistry expertise while Lead Pharma leads drug development for immune-mediated diseases and cancer.
- Chem4LS / Dr Olivier LavergnecoreConsulting agreement with Dr Olivier Lavergne (founder of Chem4LS) bringing 30+ years of pharma preclinical research experience. Expands Oxeltis' scope to provide wider range of services for drug discovery projects with integrated service offer.
- Molecular Forecaster Inc. (MFI)coreStrategic partnership announced to integrate in silico design with high-quality chemical synthesis. Combines MFI's predictive modeling and CADD solutions with Oxeltis' wet lab-based medicinal chemistry design and synthesis. Helps clients prioritize candidates, reduce design cycles, and boost productivity through streamlined project management.
- TechGateUS / Dom HebraultcoreUS sales representative agreement for business development positioning and improved customer support in North American market.
- Biocomm² / Tsutomu MoricoreJapan sales representative agreement for lead generation and client support in Japanese market.
- Genepep and BCI-PharmaminorBrought new nucleopeptide libraries to market - multifunctional linear and macrocyclic peptides providing access to new chemical space.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
OXELTIS competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec / WuXi STA: Global CRO/CDMO with extensive medicinal chemistry, custom synthesis, and oligonucleotide service offerings. Highly comparable to Oxeltis' FTE/FFS medchem and nucleoside work but at vastly greater scale and broader modality coverage.
- Pharmaron: Integrated CRO with strong medicinal chemistry, process chemistry, and custom synthesis services across China, UK, and US. Direct competitor for FTE-based drug discovery outsourcing targeting pharma and biotech clients globally.
- Eurofins Discovery: Offers medicinal chemistry, custom synthesis, and in vitro pharmacology services under the Eurofins umbrella. Comparable as a one-stop medchem outsourcing alternative to Oxeltis, particularly for European pharma clients.
- Charles River Laboratories: Major CRO with discovery services including medicinal chemistry and custom synthesis. Comparable to Oxeltis for early-stage discovery outsourcing, particularly with integrated biology and safety services.
- ChemPartner: Shanghai-based CRO with significant medicinal chemistry and custom synthesis capabilities serving global pharma and biotech. Comparable on FTE-based medchem delivery though at materially larger scale than Oxeltis.
Direct peers
- Domainex: UK-based medicinal chemistry CRO offering FTE/FFS drug discovery services to biotech and pharma. Closely comparable to Oxeltis in size, business model, and therapeutic focus, with similar reliance on European pharma clients.
- Sygnature Discovery: UK-based CRO providing medicinal chemistry, in vitro biology, and DMPK services on FTE/FFS basis. Direct peer to Oxeltis in scale, FTE/FFS hybrid model, and target client base of pharma and biotech.
- Selvita: Poland-headquartered CRO offering medicinal chemistry and custom synthesis services with European footprint. Comparable scale and service mix, with similar pharma/biotech client orientation and FTE-based engagements.
Emerging players
- Sai Life Sciences: India-based CRO expanding into discovery medicinal chemistry and custom synthesis for global pharma/biotech. Comparable emerging peer with similar FTE-based model targeting cost-effective medchem outsourcing.
- Novasep: France-based CDMO with custom synthesis and process chemistry services including nucleoside chemistry capabilities. Comparable geographic footprint and overlap with Oxeltis in fine organic chemistry and scale-up partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
OXELTIS social profiles
Digital presenceOXELTIS compliance and trust
Trust signalCompliance1 record
OXELTIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
OXELTIS leadership team
Management profileNumber of profiles
Profiles10 records
OXELTIS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OXELTIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OXELTIS
What does OXELTIS do?
OXELTIS is an independent medicinal chemistry oriented service company (CRO) that provides competencies and resources for projects involving medicinal and fine organic chemistry in pharmaceutical, diagnostic and academic research. It delivers custom synthesis of complex organic molecules including nucleos(t)ides, heterocyclic and macrocyclic compounds, phosphoramidites, and modified sugars, supporting hit-to-lead and lead optimization in drug discovery, with route scouting and scale-up from mg to ~100 g.
Is OXELTIS a public or private company?
OXELTIS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was OXELTIS founded?
OXELTIS was founded in 2010. It employs 11 to 50 people.
Where is OXELTIS based?
OXELTIS is headquartered in Montpellier, France, in the Europe region.
How does OXELTIS make money?
Four revenue lines are on record. Fee-for-Service / FFS are the primary driver. The others are FTE-based Contracts, scale-up and Production Services and partnership with Risk/IP Sharing.
Who are OXELTIS's main competitors?
Broad incumbents on record are WuXi AppTec / WuXi STA, Pharmaron, Eurofins Discovery, Charles River Laboratories and ChemPartner. Direct peers are Domainex, Sygnature Discovery and Selvita. Emerging players are Sai Life Sciences and Novasep.
Does OXELTIS have an API?
No public API is recorded for OXELTIS.
What industry is OXELTIS in?
OXELTIS's product category is Contract Research Organization (Drug Discovery Chemistry Services). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 5417 and its SIC code is 2860.